Cargando…
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
PURPOSE: To develop a risk score for patients with advanced systemic mastocytosis (AdvSM) that integrates clinical and mutation characteristics. PATIENTS AND METHODS: The study included 383 patients with AdvSM from the German Registry on Disorders of Eosinophils and Mast Cells (training set; n = 231...
Autores principales: | Jawhar, Mohamad, Schwaab, Juliana, Álvarez-Twose, Iván, Shoumariyeh, Khalid, Naumann, Nicole, Lübke, Johannes, Perkins, Cecelia, Muñoz-González, Javier I., Meggendorfer, Manja, Kennedy, Vanessa, Metzgeroth, Georgia, Fabarius, Alice, Pfeifer, Dietmar, Sotlar, Karl, Horny, Hans-Peter, von Bubnoff, Nikolas, Haferlach, Torsten, Cross, Nicholas C.P., Hofmann, Wolf-Karsten, Sperr, Wolfgang R., García-Montero, Andrés C., Valent, Peter, Gotlib, Jason, Orfao, Alberto, Reiter, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823885/ https://www.ncbi.nlm.nih.gov/pubmed/31509472 http://dx.doi.org/10.1200/JCO.19.00640 |
Ejemplares similares
-
KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019) -
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm
por: Jawhar, Mohamad, et al.
Publicado: (2017) -
P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023) -
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
por: Lübke, Johannes, et al.
Publicado: (2023) -
Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis
por: Riffel, Julia, et al.
Publicado: (2022)